<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475122</url>
  </required_header>
  <id_info>
    <org_study_id>AOI 2014-02</org_study_id>
    <nct_id>NCT02475122</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)</brief_title>
  <acronym>AzyMR</acronym>
  <official_title>Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension (PHT) that leads to esophageal varices is clinically present, at the time&#xD;
      of diagnosis, in 60% of cirrhotic patients (Groszmann NEJM 2005). Variceal bleeding is a&#xD;
      life-threatening complication. The yearly incidence of the first variceal bleeding in&#xD;
      cirrhotic patients is estimated to 4%. This risk increases to 15% when medium or large&#xD;
      varices are initially present, (D'amico Baillieres Clin Gastroenterol 1997); Therefore, for&#xD;
      patient with medium or large varices a primary prophylaxis treatment with nonselective&#xD;
      beta-blockers must be instituted decreasing risk of bleeding approximately by half (d'amico&#xD;
      Hepatology 2005).&#xD;
&#xD;
      The method to evaluate the efficacy of beta blockers treatment is the hepatic venous pressure&#xD;
      gradient (HVPG). HVPG &lt; 12 mmHg or a decrease of HVPG of 20% after beta blocker treatment&#xD;
      reduce dramatically the risk of bleeding (Feu F. Lancet 1995). But a good response (HVPG &lt; 12&#xD;
      mmHg or reduction &gt; 20%) to beta blockers was observed only in almost 30 % of patients. In&#xD;
      non responder patients, the variceal bleeding incidence is estimated to 24 % at 2 years.&#xD;
&#xD;
      In this situation, alternative treatments to beta-blockers have been suggested: endoscopic&#xD;
      ligation, which was shown to be as effective as beta blockers in primary prevention, and more&#xD;
      recently carvedilol (Reiberger, Gut 2012).&#xD;
&#xD;
      So, HVPG monitoring may provide critical information for patients. However, because of its&#xD;
      technical requirement and its invasivity, HVPG measurement is not feasible in clinical&#xD;
      practice . So, there is a general consensus to continue indefinitely beta blockers treatment&#xD;
      without control of hemodynamic efficiency (merkel J. Hepatology 2009).&#xD;
&#xD;
      Previous studies have suggested the interest of azygos blood flow measurements for evaluating&#xD;
      hemodynamic changes in the esophageal collateral vessels of patients with portal hypertension&#xD;
      (Bosch J. Hepatology 1985 ). More recently Magnetic Resonance Imaging (MRI) has been reported&#xD;
      to be an efficient technique to assess azygos blood flow (Gouya Radiology 2011) in cirrhotic&#xD;
      patients. Its feasibility is obviously higher than HVPG measurement.&#xD;
&#xD;
      However, in the same way that HVPG, a large-scale implementation in clinical practice of&#xD;
      azygos blood flow measurement by MRI requires to specify minimal absolute threshold, or&#xD;
      relative post-therapeutic decrease, related with no variceal bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number an severity of adverse events occurring during follow up</measure>
    <time_frame>during 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Bleeding Esophageal Varices</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>open-label study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open-label study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>azygos blood flow measurements by MRI</intervention_name>
    <arm_group_label>open-label study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cirrhotic patients requiring β blocker in primary prophylaxis of bleeding esophageal&#xD;
        varices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 year's old&#xD;
&#xD;
          -  life expectancy of less than one month&#xD;
&#xD;
          -  Patient already has a vasoactive treatment&#xD;
&#xD;
          -  patient with CHC or portal vein thrombosis&#xD;
&#xD;
          -  patient without social security or deprived of freedom&#xD;
&#xD;
          -  contraindication to MRI&#xD;
&#xD;
          -  contraindication to beta-blockers&#xD;
&#xD;
          -  mental state does not allow the signing of an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Measurement of azygos blood flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

